Wall Street Zen Downgrades Telix Pharmaceuticals (NASDAQ:TLX) to Sell

Telix Pharmaceuticals (NASDAQ:TLX) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Other equities analysts have also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Telix Pharmaceuticals in a research note on Wednesday, January 21st. Weiss Ratings restated a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Wednesday, January 21st. Royal Bank Of Canada upgraded shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research report on Monday, January 19th. Finally, Citigroup reaffirmed a “buy” rating on shares of Telix Pharmaceuticals in a report on Tuesday, January 27th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Telix Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.

Telix Pharmaceuticals Stock Up 2.0%

NASDAQ:TLX opened at $7.10 on Friday. The business’s 50-day moving average price is $8.07 and its 200 day moving average price is $9.69. Telix Pharmaceuticals has a 52-week low of $6.87 and a 52-week high of $30.36.

Institutional Investors Weigh In On Telix Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Rhumbline Advisers grew its position in Telix Pharmaceuticals by 117.3% during the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after purchasing an additional 1,392 shares in the last quarter. IHT Wealth Management LLC acquired a new stake in shares of Telix Pharmaceuticals in the second quarter worth $213,000. Blair William & Co. IL acquired a new stake in shares of Telix Pharmaceuticals in the second quarter worth $217,000. JPMorgan Chase & Co. purchased a new position in shares of Telix Pharmaceuticals during the third quarter valued at $243,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in Telix Pharmaceuticals during the second quarter valued at $297,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.